Document Type
Article
Publication Date
5-1-2025
Original Citation
Agoro R,
Churchill G.
Challenges and opportunities for conceiving genetically diverse sickle cell mice. Trends Mol Med. 2025;31(5):413-23.
Keywords
JMG, Animals, Anemia, Sickle Cell, Mice, Disease Models, Animal, Humans, Genetic Variation
JAX Source
Trends Mol Med. 2025;31(5):413-23.
ISSN
1471-499X
PMID
39643521
DOI
https://doi.org/10.1016/j.molmed.2024.11.004
Grant
This work is partially supported by National Institutes of Health (NIH) grant R00-DK129705 (R.A.).
Abstract
A milestone in sickle cell disease (SCD) therapeutics was achieved in December 2023 with the FDA-approved gene therapy for patients aged 12 years and older. However, these therapies may only suit a fraction of patients because of cost or health risks. A better understanding of SCD outcome heterogeneity is needed to propose patient-specific pharmacological interventions. To achieve this, humanized and genetically diverse mouse models are essential for associating candidate genotypes with specific hematological traits, organ function, and disease resilience. Here, we discuss the challenges and opportunities in developing genetically diverse sickle cell mice (GDS mice). These models are expected to complement current approaches in SCD research and enhance our understanding of SCD heterogeneity and anemia.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.